Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.

Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.
复制标题

DOI:
10.1111/tri.12850
复制
发表时间:
2016-11
期刊:
Transplant international : official journal of the European Society for Organ Transplantation
影响因子:
--
通讯作者:
Lentine KL
Lentine KL
中科院分区:
其他
文献类型:
--
作者:
Dharnidharka VR;Schnitzler MA;Chen J;Brennan DC;Axelrod D;Segev DL;Schechtman KB;Zheng J;Lentine KL

文献摘要

参考文献

被引文献

相似文献

We examined integrated national transplant registry, pharmacy fill and medical claims data for Medicare-insured kidney transplant recipients in 2000–2011 (n=45,164) from the United States Renal Data System to assess efficacy and safety endpoints associated with 7 early (first 90 days) immunosuppression (ISx) regimens. Risks of clinical complications over 3 years according to IS regimens were assessed with multivariate regression, including adjustment for covariates and propensity for receipt of a non-reference ISx regimen. Compared to the reference ISx (thymoglobulin induction with tacrolimus, mycophenolate and prednisone maintenance), sirolimus-based ISx was associated with significantly higher 3-year risks of pneumonia (adjusted hazard ratio, aHR 1.45;P<0.0001), sepsis (aHR 1.40;P<0.0001), diabetes (aHR 1.21;P<0.0001), acute rejection (AR; adjusted odds ratio, aOR 1.33;p<0.0001), graft failure (aHR 1.78;p<0.0001), and patient death (aHR 1.40;P<0.0001), but reduced skin cancer risk (aHR 0.71;p<0.001). Cyclosporine-based IS was associated with increased risks of pneumonia (aHR 1.17;p<0.001), sepsis (aHR 1.16;p<0.001), AR (aOR 1.43;p<0.001) and graft failure (aHR 1.39p<0.001), but less diabetes (aHR 0.83;p<0.001). Steroid-free ISx was associated with reduced risk of pneumonia (aHR 0.89;p=0.002), sepsis (aHR 0.80;p<0.001) and diabetes (aHR 0.77;p<0.001) but higher graft failure (aHR 1.35;p<0.001). Impacts of ISx over time warrant further study to better guide ISx tailoring to balance efficacy and morbidity.
DOI: 10.1001/jama.2011.1592
发表时间: 2011-11-02
影响因子: 120.7
作者:
Engels, Eric A.;Pfeiffer, Ruth M.;Fraumeni, Joseph F., Jr.;Kasiske, Bertram L.;Israni, Ajay K.;Snyder, Jon J.;Wolfe, Robert A.;Goodrich, Nathan P.;Bayakly, A. Rana;Clarke, Christina A.;Copeland, Glenn;Finch, Jack L.;Fleissner, Mary Lou;Goodman, Marc T.;Kahn, Amy;Koch, Lori;Lynch, Charles F.;Madeleine, Margaret M.;Pawlish, Karen;Rao, Chandrika;Williams, Melanie A.;Castenson, David;Curry, Michael;Parsons, Ruth;Fant, Gregory;Lin, Monica
通讯作者: Lin, Monica
DOI: 10.2215/cjn.03080707
发表时间: 2008-07-01
影响因子: 9.8
作者:
Lentine, Krista L.;Rey, Lisa A. Rocca;Brennan, Daniel C.
通讯作者: Brennan, Daniel C.
DOI: 10.1097/01.tp.0000184006.43152.8d
发表时间: 2005-10-15
期刊: TRANSPLANTATION
影响因子: 6.2
作者:
Kauffman, HM;Cherikh, WS;Kahan, BD
通讯作者: Kahan, BD
DOI: 10.1056/nejmoa067411
发表时间: 2007-12-20
影响因子: 158.5
作者:
Ekberg, Henrik;Tedesco-Silva, Helio;Halloran, Philip F.
通讯作者: Halloran, Philip F.
DOI: 10.1681/asn.2004070580
发表时间: 2005-02-01
影响因子: 13.6
作者:
Lentine, KL;Brennan, DC;Schnitzler, MA
通讯作者: Schnitzler, MA